Sergey Alexeev is an economist–statistician specialising in trial-based and quasi-experimental evaluation, predictive modelling, and cost–benefit analysis. His training spans GSOM–St Petersburg (BFin, Trinity College Dublin exchange), Université Paris-Dauphine (MSc, Finance & Control, cum laude), York University (MA Economics), and a PhD in Economics at UTS. Early-career work at NDARC with Prof Don Weatherburn and BOCSAR used linked administrative data to study drug and alcohol policy, shaping public debate and reform. At the NHMRC Clinical Trials Centre, he was methodological lead on the ENCORE cluster RCT (International Journal of Nursing Studies, 2024) and co-authored the CARE protocol for robust cluster-trial inference; an ARC DECRA program on innovative randomised experiments is proposed.

Sergey currently leads HOPE (judge-leniency IV to estimate the causal health effects of imprisonment) and EVIDENCE (evaluating drug policy and harm reduction at scale), and builds AI-enabled evidence-synthesis pipelines and place-based decision dashboards for small Australian towns. He partners with Aboriginal and Torres Strait Islander communities through advisory and lived-experience panels, serves on the NSW Population & Health Services Research Ethics Committee (PHSREC), and is committed to Indigenous data sovereignty and open, replication-ready science (via I4R). His service includes the editorial board of the International Journal of Drug Policy and supervision of HDR and master’s students. His research has been featured in 7 News, The Age, and The Guardian. He is of Ingrian-Finn heritage. More about his research and publications is available at alexeev.pw, and his full CV is available here.